Clinical trials: Oligometastatic Colorectal Carcinoma
Colorectal Cancer Metastatic
Local Consolidative Therapy in Colorectal Cancer
This is a Phase II randomized multisite trial to study the effect of a combination of local consolidative therapy with systemic therapy in subjects with oligometastatic colorectal cancer who have progressed on the first line of…
- Trial name
- NCT05062720
- Testing
- Local consolidative therapy
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Oligometastasis, Lung Cancer
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients…
- Conditions
- Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
- Trial name
- ID-COMET (NCT06563388)
- Testing
- Stereotactic Ablative Radiotherapy, Best Practice
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Roswell Park Cancer Institute
Oligometastatic Disease, Liver Metastases
Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal…
- Conditions
- Oligometastatic Disease, Liver Metastases, Colorectal Cancer
- Trial name
- NCT04973007
- Testing
- Gadoxetate disodium, Gadobenate dimeglumine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Colorectal Cancer
Plasma Multi - Omics Detection for Evaluating Efficacy and Recurrence Risk in Oligometastatic Colorectal Cancer Conversion Therapy
This prospective study (PMEIRR-OCCCT) evaluates the utility of plasma multi-omics-including circulating tumor DNA (ctDNA), cell-free RNA (cfRNA), proteomics, and metabolomics-in assessing response to conversion therapy and…
- Trial name
- PMEIRR - OCCCT (NCT07492238)
- Testing
- Plasma Multi - omics Detection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiujuan Qu
Gynecologic Cancer, Skin Cancer
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.
- Conditions
- Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- OligoRARE (NCT04498767)
- Testing
- Stereotactic body radiotherapy, Palliative RT
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Carcinoma Metastatic in the Liver
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals…
- Trial name
- METEORITE (NCT06555133)
- Testing
- yttrium-90 radioembolization
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Anal Cancer, Locally Advanced Squamous Cell Carcinoma
Circulating Biomarkers in Patients With Anal Cancer Treated With Induction Chemotherapy
To investigate the prognostic and predictive value of plasma HPV (pHPV) prior, during and after induction chemotherapy (ICT) in locally advanced squamous cell carcinoma of the anus (SCCA) or synchronous metastatic SCCA patients…
- Conditions
- Anal Cancer, Locally Advanced Squamous Cell Carcinoma, Oligometastatic Disease, Circulating Tumor Cell
- Trial name
- NCT05233540
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Aarhus University Hospital
Metastasis, Metastatic Breast Cancer
The Impact of Radiotherapy on Oligometastatic Cancer
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR).
- Conditions
- Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT05933876
- Testing
- To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR)., To propose a diagnostic test to determine the effectiveness of SABR., To propose a diagnostic test for Oligometastatic Cancer (OC).
- Where
- 21 sites in Spain
- Volunteers
- 2,000 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Colorectal Carcinoma, Liver Metastases
Microwave Ablation Versus Stereotactic Body Radiotherapy for Colorectal Liver Metastases in Oligometastatic Disease: a Prospective, Randomised, Phase 2 Trial
The LAVA-CRLM trial (Local Ablation Versus Ablative radiotherapy in ColoRectal Liver Metastases) is a prospective, randomised, phase 2 study designed to compare local control and safety of microwave ablation (MWA) versus…
- Trial name
- LAVA-CRLM (NCT03654131)
- Testing
- MWA, SBRT
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Oligometastatic Colorectal Carcinoma
- Trial name
- NCT05673148
- Testing
- Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation
- Where
- 189 sites in United States, Canada
- Volunteers
- 146 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Colorectal Cancer, Oligometastatic Disease
Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites
A small number of colorectal cancer patients with limited oligometastases may be candidates for local treatment of metastases (e.g., resection, ablation).
- Trial name
- SIRIUS (NCT05375708)
- Testing
- Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
- Where
- 4 sites in Netherlands
- Volunteers
- 93 people
- Sponsor
- UMC Utrecht
Colorectal Cancer
The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
This is a prospective, single-center, single-arm phase II clinical trial. This study aims to evaluate the safety and tolerability of stereotactic ablative radiotherapy (SABR) in combination with Sintilimab, and to examine the…
- Trial name
- NCT04535024
- Testing
- Stereotactic Ablative Radiotherapy (SABR), Sintilimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer, Metastases
Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer
This study tries to evaluate the role of chemoradiation with capecitabine and bevacizumab in oligometastatic patients neither being progressive nor resectable after chemotherapy.
- Trial name
- OLGA (NCT01759238)
- Testing
- Capecitabine, Bevacizumab, Radiotherapy
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Oligometastatic Disease
Prediction of True Oligo-metastatic Disease.
In recent years, the scientific community has recognized the need to differentiate between poly- and oligo-metastatic disease (OMD) in oncology due to their distinct clinical and biological behavior.
- Trial name
- PREDICTION (NCT05806151)
- Testing
- Genetic and immunologic assessments
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Cancer, Oligometastatic Disease
RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment including the impact on survival, compared to continued standard first-line systemic…
- Trial name
- RESOLUTE (NCT05862051)
- Testing
- Local Ablative Therapy, Standard first-line systemic treatment
- Where
- 9 sites in Australia
- Volunteers
- 6 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Colorectal Cancer
Low and Intermediate Risk OliGometastatic ColoREctal CancEr PatieNts Treated with Stereotactic ABlative Radiotherapy
This is an experimental study without drug or device, randomized, open-label, non-profit, sponsored by the IRCCS Sacro Cuore Don Calabria Hospital in Negrar, which will take place at the Department of Advanced Oncological…
- Trial name
- GREENLaIT-SABR (NCT06310564)
- Testing
- SABR
- Where
- Italy
- Volunteers
- 204 people
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Colorectal Cancer, Metastatic Cancer
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
A study investigating if analysis of circulating tumor DNA (ctDNA) can guide adjuvant treatment in patients with advanced colorectal cancer (CRC)
- Trial name
- OPTIMISE (NCT04680260)
- Testing
- Standard of care, Circulating tumor DNA guided treatment approach
- Where
- 2 sites in Denmark
- Volunteers
- 350 people
- Sponsor
- Karen-Lise Garm Spindler
Colorectal Cancer Metastatic
PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)
PRELUDE-1 study is a pilot intervention trial that aims to describe the immunologic and genetic evolutions induced by stereotactic body radiationtherapy (SBRT) treatment in oligometastatic Colorectal Cancer (omCRC) patients with…
- Trial name
- PRELUDE-1 (NCT04854213)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute, Naples
Oligometastatic Disease
125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer
Most patients with metastatic cancer eventually develop resistance to systemic therapy. A subset of patients experience oligoprogression, characterized by progression at a limited number of lesions while other disease sites…
- Trial name
- NCT07333651
- Testing
- Standard-of-Care Systemic Therapy, 125I Seed Implantation
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Li Min